@article{ATM30450,
author = {Yan Wang and Kai Chen and Yaping Yang and Luyuan Tan and Lili Chen and Liling Zhu and Fengxi Su and Xue Liu and Shunrong Li},
title = {Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer},
journal = {Annals of Translational Medicine},
volume = {7},
number = {20},
year = {2019},
keywords = {},
abstract = {Background: Male breast cancer (MBC) is a rare malignancy. We aimed to analyze the incidence trends, clinicopathological characteristics, and survival outcomes in early MBC comparison with early female breast cancer (FBC).
Methods: We included eligible MBC and FBC patients with stage I–II disease in the Surveillance, Epidemiology, and End Results (SEER) database from 2000–2015. Joinpoint regression was used to evaluate the trends in age-adjusted incidence. A one-to-four propensity score matching (PSM) analysis was performed to reduce bias in a retrospective study. Survival outcomes were evaluated using Kaplan-Meier analyses with the log-rank test and Cox proportional hazards regression analysis.
Results: Trends in the age-adjusted incidence rates of early MBC were stable [2000–2015, annual percentage change (APC) =0.50, 95% confidence interval (CI): –0.1 to 1.1, P=0.102]; however, the incidence of early FBC changed significantly over the time period (2000–2015, APC = 0.30, 95% CI: 0.0 to 0.6, P=0.045). In the matched cohort, unmarried status, higher grade, larger tumor size, and advanced lymph node (LN) status were associated with a higher risk of breast cancer death and death of any causes both in early MBC and FBC patients. The hormone receptor (HR) status was as a prognostic factor in FBC patients, but not in MBC. Early MBC had worse breast cancer-specific survival (BCSS) and overall survival (OS) than early FBC in stage I, stage II and HR-positive subgroup of patients.
Conclusions: The biological behavior, clinicopathological features, and clinical outcomes of early MBC are different from that of FBC. Further studies on individualized treatment approaches in MBC are needed.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/30450}
}